RedMedEd

RedMedEd

Overview

At RedMedEd, increasing clinician competence and improving patient care is the name of the game.

With a track record of excellence in CME and a wide range of innovative gamification and interactive learning designs, the RedMedEd team delivers initiatives that are fresh, rigorous, engaging, and memorable.

When CME is done well, clinicians learn and patients win.


Cytokines, Janus Kinase Inhibitors, and Small-Molecule Therapies, Oh My!: New Inroads Into Rheumatoid Arthritis Management

Although the introduction of biologic agents has transformed treatment paradigms for rheumatoid arthritis (RA), a considerable proportion of patients do not respond sufficiently to these therapies. A potential new therapeutic alternative for these patients is small-molecule inhibitors, which offer targeted inhibition of intracellular pathways that can be achieved via oral administration. To real...
University of Chicago Pritzker School of Medicine and RedMedEd

Integrating Therapeutic Advances to Improve Current Practices in Myeloma Patient Care

Improving outcomes for patients with multiple myeloma requires building on the foundation of current therapies with new agents and combinations, recognizing the nature of each individual patient’s disease, and providing a personalized approach to treatment. This activity uses evidence-based presentations and case study vignettes to present the latest information on selecting the most appropria...
Multiple Myeloma Research Foundation, RedMedEd, and Penn State College of Medicine

Multiple Myeloma Expert Roundtable: Risk Assessment, Minimal Residual Disease, and Precision Medicine

The clinical multiple myeloma arena has undergone significant advancement in recent years; not only have 10 drugs been added to the armamentarium, but there have been important developments in diagnosis and staging, minimal residual disease (MRD) monitoring, and supportive care. The expansion of clinical options brings both opportunities and challenges for health care providers who see myeloma p...
Multiple Myeloma Research Foundation, RedMedEd, and Penn State College of Medicine

Multiple Myeloma Expert Roundtable: Stem Cell Transplantation, Maintenance Therapy, and Relapsed/Refractory Disease

With numerous recent advances in available treatments and options for diagnosis and staging, disease monitoring, and supportive care, the outlook for patients with multiple myeloma has never been brighter. However, this expansion of clinical options has also introduced potentially daunting challenges for the health care providers charged with the care of these patients. This activity presents...
Multiple Myeloma Research Foundation, RedMedEd, and Penn State College of Medicine

Multiple Myeloma Patient Management: Embracing New Advancements, Overcoming New Challenges

The multiple myeloma clinical landscape has evolved significantly, with not only 10 new drugs but also new staging standards (ie, the R-ISS), imaging techniques, and maintenance therapy options added in the last 12 years. To help hematologist-oncologists keep pace with these advancements and to illustrate their optimal use in practice, this Virtual Practice reviews two multiple myeloma patient c...
Multiple Myeloma Research Foundation, RedMedEd, and Penn State College of Medicine

RME Hot Seat – Severe Asthma: Clinical Phenotypes and the Emerging Age of Personalized Therapy

Patients with severe treatment-resistant asthma—estimated to account for 4%–10% of all asthma cases—are characterized by persistent symptoms, compromised lung function, and a significantly increased frequency and severity of high-risk outcomes. These patients are typically insensitive to corticosteroid treatment, except at very high doses—and are thus at greater risk for several serious ...
RedMedEd and Rutgers Biomedical and Health Sciences

Scale, Bail, or Fail – The CDK4/6 Inhibition Edition

Preclinical and clinical findings suggest that CDK4/6 inhibition may confer therapeutic benefits in numerous tumor types and improve outcomes in patients with mantle cell lymphoma, liposarcoma, melanoma, and non–small cell lung cancer. Additionally, studies of CDK4/6 inhibition of cancers of the prostate, lung, skin, and central nervous system are currently under way. In the format of an en...
University of Cincinnati and RedMedEd

Severe Asthma Virtual Practice: Clinical Phenotypes and the Emerging Age of Personalized Therapy

Up to 10% of asthma patients have severe, treatment-resistant disease that is associated with a greater incidence of emergency room visits, hospitalizations, and other high-risk outcomes. Often, these patients are only responsive to corticosteroid treatment when it is given at very high doses, which over time can lead to type 2 diabetes, osteoporosis, dyspeptic disorders, and cataracts. The FDA...
RedMedEd and Rutgers Biomedical and Health Sciences

YouTube Google+ Pinterest Twitter LinkedIn Facebook SlideShare
RXinsider, CESearchEngine.com, and our advertising partners do not endorse and do not verify the accuracy of the content in the activities presented on the CESearchEngine.com website or within our mobile apps. RXinsider, CESearchEngine.com, and our advertising partners are not responsible for errors, omissions, or misrepresentations contained within activities presented on the CESearchEngine website or or within our mobile apps. For complete details, please read the CESearchEngine.com Terms of Service. Site Map.